Skip to main content
Top
Published in: Pain and Therapy 1/2016

Open Access 01-06-2016 | Original Research

Oxycodone and Naloxone Combination: A 12-Week Follow-up in 20 Patients Shows Effective Analgesia Without Opioid-Induced Bowel Dysfunction

Authors: Gareth P. Jones, Shiva S. Tripathi

Published in: Pain and Therapy | Issue 1/2016

Login to get access

Abstract

Introduction

Opioid analgesics are widely regarded to be highly effective but are equally known for their side effects on the bowel. A new combination of the opioid analgesic oxycodone and naloxone has been developed to combat opioid-induced bowel dysfunction (OIBD) whilst still being effective as an analgesic. The aim of this observational study was to assess the analgesic efficacy of this new combination and to analyze its effect on bowel function.

Methods

Twenty-six patients underwent a trial of this new combination, with 21 patients reaching week 8 and 18 reaching week 12.

Results

A significant reduction was seen in the pain severity score at weeks 4, 8, and 12 (P < 0.05), and a significant improvement in the bowel function index was again seen at these points (P < 0.001 at week 4 and 12, P < 0.05 at week 8). In the patients’ global impression of change, 83.3% of patients rated the new medication as an improvement compared to their previous regimen, and 87.5% rated it overall as “good” or “very good.”

Conclusion

This small single-center study suggests that the use of ONC in selected patients could lead to an improvement in pain severity and pain interference with a significant improvement in OIBD. Compliance with the combination is good, and it is generally well tolerated.
Literature
1.
go back to reference Kalso E, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.CrossRefPubMed Kalso E, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–80.CrossRefPubMed
2.
go back to reference Jones GP, et al. Targinact: an effective opioid combination, without the associated bowel problems. Abstracts from the 2014 world institute of pain. Pain Prac. 2014;14(Suppl 1):15. Jones GP, et al. Targinact: an effective opioid combination, without the associated bowel problems. Abstracts from the 2014 world institute of pain. Pain Prac. 2014;14(Suppl 1):15.
3.
go back to reference IBM Corp. IBM SPSS Statistics Version 20. 2011. IBM Corp. IBM SPSS Statistics Version 20. 2011.
4.
go back to reference Sandner-Kiesling A, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64(6):763–64.CrossRefPubMedPubMedCentral Sandner-Kiesling A, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64(6):763–64.CrossRefPubMedPubMedCentral
5.
go back to reference Lazzari M, et al. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysis. Drug Des Devel Ther. 2015;9:5863–72.CrossRefPubMedPubMedCentral Lazzari M, et al. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysis. Drug Des Devel Ther. 2015;9:5863–72.CrossRefPubMedPubMedCentral
6.
go back to reference Gatti A, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther. 2013;30(1):41–59.CrossRefPubMed Gatti A, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther. 2013;30(1):41–59.CrossRefPubMed
7.
go back to reference Poelaert J, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015;37(4):784–92.CrossRefPubMed Poelaert J, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015;37(4):784–92.CrossRefPubMed
8.
go back to reference Vondrackova D, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–54.CrossRefPubMed Vondrackova D, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–54.CrossRefPubMed
9.
go back to reference Lowenstein O, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–43.CrossRefPubMed Lowenstein O, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–43.CrossRefPubMed
10.
go back to reference Meissner W, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.CrossRefPubMed Meissner W, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.CrossRefPubMed
11.
go back to reference Simpson K, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–12.CrossRefPubMed Simpson K, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–12.CrossRefPubMed
12.
go back to reference Nadstawek J, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62(8):1159–67.CrossRefPubMedPubMedCentral Nadstawek J, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62(8):1159–67.CrossRefPubMedPubMedCentral
Metadata
Title
Oxycodone and Naloxone Combination: A 12-Week Follow-up in 20 Patients Shows Effective Analgesia Without Opioid-Induced Bowel Dysfunction
Authors
Gareth P. Jones
Shiva S. Tripathi
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 1/2016
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-016-0051-4

Other articles of this Issue 1/2016

Pain and Therapy 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.